Aristotle Atlantic Partners, LLC Supernus Pharmaceuticals, Inc. Transaction History

Aristotle Atlantic Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$14.45 - $24.69 $604,400 - $1.03 Million	-41,827 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$19.93 - $29.13 $185,667 - $271,375	-9,316 Reduced 18.22%	41,827 $993,000
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $1,018 - $1,334	-40 Reduced 0.08%	51,143 $1.41 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $359 - $466	12 Added 0.02%	51,183 $1.69 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $884,429 - $1.13 Million	26,989 Added 111.61%	51,171 $1.79 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $105,842 - $169,918	3,432 Added 16.54%	24,182 $803,000
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $253,575 - $344,137	5,750 Added 38.33%	20,750 $1.24 Million
Q1 2018 Sep 10, 2018	BUY	$37.15 - $46.9 $557,250 - $703,500	15,000 New	15,000 $687,000
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $557,250 - $703,500	-15,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $546,000 - $639,000	15,000	15,000 $598,000

282

61.1M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Aristotle Atlantic Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Aristotle Atlantic Partners, LLC with notifications on news.